The present study deals with isolation of different polysaccharides from Plantago Ovata husk and their use in designing the controlled release Gastro-Retentive (GR) floats of piroxicam (PRC). Gastroretentive floats are actually drug release (DR) moieties of low density used to retain the drug in stomach for maximum time to increase its bioavailability. The polysaccharides extracted from P. Ovata were selected due to its therapeutic impacts and ease in accessibility although synthetic polymers have already been utilized for designing such types of floats. The floats of that fraction were selected for designing further formulations having least lag time with maximum drug release retarding ability. For modifying the drug release (DR) rate; flax seed gel, gum tragacanth and Stearic acid were used as variables. The direct compression technique was used for compression and floats were characterized for uniformity in weight, drug content, friability and in vitro buoyancy. All fractions were characterized by FTIR, TGA, GPC and SEM study to find the nature of polysaccharide, predicting its stability and compatibility with human body. Some mathematical tools i.e. kinetic study and regression analysis (RA) were applied to find the effect of different variables on DR rate and closeness among the theoretical and experimental DR profile. The ethanol separated part (ENa) was seen to be most suitable in view of its better swelling ability and minimum lag time. The formulation S4F9 was seem to be best fitted due to its minimum lag time, best drug entrapping ability and best suitability to Higuchi's model (R 2 = 0.957) and Power law (R 2 = 0.963). The DR mechanism was found to be nonFickian diffusion (n > 0.45). Keywords: Polysaccharide Gels; GR floats; GPC; FTIR; TGA; 3 2 Factorial design; Lag time Introduction The regular polysaccharides and their derivatives are richly utilized as a part of pharmaceutical formulations of various types where they assume an imperative part as binder, film formers, DR modifiers, viscosity enhancers, stabilizers and suspending agents [1]. In a few cases, proteins, starches and plants hydro-gels are being used as a medium in CDDS (control Karim et al.
Introduction
The regular polysaccharides and their derivatives are richly utilized as a part of pharmaceutical formulations of various types where they assume an imperative part as binder, film formers, DR modifiers, viscosity enhancers, stabilizers and suspending agents [1] . In a few cases, proteins, starches and plants hydro-gels are being used as a medium in CDDS (control drug delivery system) but most of polymers used have no therapeutic importance. Presently an exceptional consideration is being paid on selection of polymers having double characters i.e. restorative significance alongside DR retardant. The Plantago Ovata is an herbal plant and generally used as a drug for treating unending ailments i.e. coronary heart diseases, reducing the blood glucose level in blood. In this study, focus is towards the segregation of new swellable biopolymer from P. Ovata husk and their utilization as matricing agent for designing the gastroretentive floats. The GR floats are actually floating drug tablets used for increasing the gastric residence time to increase the drug bioavailability. The swelling property of husk gel is reported in literature but its fractionation and then their use in CDDS is under progress [2] . It is most suitable than other synthetics gels due to being non-toxic, minimal effort of extraction, simplicity of accessibility, high partiality for water. It is water insoluble and mechanical activity of nutritious trench can't absorb it. There are so many mechanisms for controlling the DR and one such mechanism is swelling through hydration which is apparently present in P. Ovata seed husk. Swelling increases the pore volume of hydrogel and permits the dispersion of gastric medium for discharging the absorbed medicine in gel and thermal study reveals that it can face the environmental changes due to its stability at room temperature [3] [4] [5] [6] [7] . The PRC is a viable NSAID drug utilized for the treatment of joint inflammation [8] . Its typical dose is 20 mg yet some time two fold doses are required to keep up the drug plasma level. The half-life of drug is around 40 h in man and is metabolized into dynamic metabolites and peak plasma level is achieved after 2 h subsequent to taking single dosage and it stayed dynamic over next 48 h because of expanded plasma halflife. The drug has exceptionally protein binding capacity and in this way it replaces numerous different types of drugs that are only limited to proteins. The present study was directed to prepare PRC floats utilizing P. Ovata seed husk and some other characteristic polysaccharides as DR modifier and was compared to sustained release marketed tablets [9, 10] . This drug is utilized to assuage the joint inflammation. It works by preventing the production of some chemicals (prostaglandins) which are involved in mediation of pains in stiffness, swelling, tenderness and provocative conditions in joint inflammation [11 -13] . The goal was to prepare GR floats of PRC. These extracted fractions meet all the physiological prerequisites required for matrix utilized for preparing the gastroretentive controlled release tablets i.e. being insoluble in water, having low density, high swelling/ re-swelling ability. By adjusting the matricing variables, the DR mechanism can be adjusted. Figure 1) were added separately in different portion of filtrate to coagulate the different insoluble fractions from filtrate. The isolated gels were dialyzed, dried and finely ground to fine powder. The fine powder was used as matricing agent for drug to design GR floats. The citrus acid and NaHCO3 was mixed in matrix to reduce the LT (The time after which tablets start floating on the dissolution medium) and increase the gastric retention time for increasing the bioavailability of drug. From ratio of different average molar masses, the polydispersity index (PDI) was calculated (Eq. 4) PDI = Mw / Mn (Eq. 4) For GPC analysis, pullulan and dextran were used as standard (Polymer Standards Service, Germany). Dimethyl sulphoxide was used as eluent in a system that is fitted with two columns functioning at run rate 0.5 mL min -1 at 70°C using volume 50 µL as injection.
SEM studies
The pellets of all fractions were compressed at hydraulic press at pressure 3000 Psi mounted with Ag-painted aluminum stubs coated with Au working at accelerating voltage 10 kV. Different micrographs were taken at different magnifications to study the surface morphology. Greater the roughness on surface, greater is the adsorption power of gel to adsorb and uneven surface has greater absorption tendency. The drug release behavior of ENa was matching with the set criteria (minimum lag time), therefore other fractions were ignored. Moreover it was found that different fractions have different drug release behavior with different drugs. The ENa fraction was best fitted therefore was selected as a standard for designing the desired drug release floats and therefore its GPC chromatogram was inserted. Calibration curve A stock solution of PRC (10 mg/100 mL) was prepared in simulated gastric fluid (SGF) [pH 1.2 HCl (5 mL HCl concentrated in 991.5 mL distilled water) with purified pepsin]. The prepared samples were diluted 10 times and diluted medium was further diluted to 50% to obtain a solution of known concentration solutions ranging from 0.5 -2.5 µg/m L. The absorbance was measured spectro-photometrically at 234 nm with the mean data (n = 5). The calibration graph for PRC ( Figure 2a Table 1 ) are shown. In equation, y is DR%, X is the amount of drug released. By putting the value of other variables, we can calculate the value of X during that interval. This plot is drawn using DR data taken from pure drug only without any matrix. ⃰ Fractions extracted from hydrogel solution of NaOH using solvents, MNa = Methanol, ENa= Ethanol, AANa = acetic acid, Clf Na=chloroform, ANa= acetone, H= whole gel and Cstd= standard tablet
The floats prepared using ENa showed minimum LT, therefore ENa was selected as matricing agent for further study. Although DR from all fractions was generally less than required for achieving effective drug blood plasma level. Further formulations were designed to find optimized formulation. Different batches were prepared with different amounts of excipients using ENa as major matricing agent to explore the most potential formulation.
Preparation of matrix tablets
The wet granulation technique was used to prepare the ENa floats. Excipients including drug were blended geometrically and formulations were designed as per factorial model ( Table 2 ). For sorption of drug, ENa was put in clear drug solution for maximum swelling. After maximum swelling, the swelled lump was kept in long container having non-sticky surface fitted with pump. The whole mass was splashed through little opening on inner side of container fitted with heating heated at 45 0 C. The dried granules were collected and compacted in to floats under pressure of 10 kN on single punch machine fitted with 9.5 mm flat punch. The iPrOH was added in blended material to homogenize the swelling rate and magnesium stearate was added as glident. Analysis of friability, drug content and stability study Ten floats weigh equal to 100 mg were transferred to 100 mL volumetric flask and subsequent to blending in solution of pH 1.2. The blend was filtered and 1 mL of filtrate was further diluted to form a solution (100 µg m L -1 ). The analysis was conducted at λmax 234 nm using UV -Visible spectrophotometer. To test the friability, floats were kept in a drum rotating at a speed of 30 rpm min -1 and sample was rotated at a speed 100 revolutions min -1 for 5 min to find the disintegration of float. The floats were dusted off and were weighed again and % loss in weight was calculated from equation. Friability = (initial mass -final mass) / initial mass × 100
Dissolution study
The USP paddle dissolution apparatus-II was used to study the DR at 37 o C ± 0.1 o C rotating at 50 rpm. The buffer pH 1.2 was taken in each container (900 mL). After fixed time interval, 5 mL sample was taken out and was analyzed at double beam spectrophotometer (Schimadzu UV-1700) at λmax 234 nm. After withdrawal of test sample, buffer medium kept at same temperature was added to have the volume 900 mL. The DR % was calculated from withdrawn sample.
Statistical analysis
The 3 3 full factorial designs (Table 1) were used for RA (regression analysis) to determine the effect of independent variables on DR%. The statistical equation was derived to find the effect of all variables. S% = ß0 + ß1 X1 + ß2 X2 + ß12 X1X2 + ß1 X1 2 + ß2 X1 2 Where S% (DR %); ß is coefficient of regression; X1 and X2 stands for effect of both independent variables ; X1X2 is the interactions factor between X1 and X2 and X1 2 and X1 2 are quadratic terms.
Result and discussion Description of ENa Elemental analysis
Each sample was analyzed thrice. The percentage of Carbon was found to be lower (40.2%) than in other natural polysaccharides (45.0%) and Hydrogen content was greater (6.5%) than observed in other polysaccharides (6.0%) due to its better water upholding capability. The N was not detected in any sample showing that protein was absent in all sample.
FT IR spectroscopy
The FTIR spectrum of ENa (Figure 4) shows that following absorbance were indicated. The assignment at 3374-3443 cm -1 was due to -OH stretching broad band and a peak at 2882-2918 cm -1 was due to saturated C-H stretching and absorbance at 1563-1638 cm -1 The molar mass distribution of all hydrogels was determined by GPC study ( Table 2 ). The heterogeneity was determined from polydispersity index (PDI) that is the ratio of Mw and Mn. The molar mass averages for a monodisperse polymer are almost equal and their PDI values are close to 1. In a poly disperse system, Mz>Mw >Mn as the result the PDI value is greater than 1. For all fractions, the molar mass distribution is shown (Table 3 ) and their PDI are found to be; ANa = 2.87, AANa = 2.69, MNa = 3.16, ClfNa = 3.78 and ENa = 3.75. From these values it was found that their heterogeneity index is ranging from 2.682 to 3.781 indicating that these hydrogels are showing poly disparity. Scanning electron microscopy Different photographs were taken at different magnifying power to study the surface morphology. The SEM image of ENa is shown for representative purpose ( Figure 5 ).
Figure 5. Scanning electron microscopy of ENa

Thermal Analysis
The thermal analysis was conducted for isolated fractions ranging from room temperature to 600°C. An endothermic weight loss (10-12%) was seen at 190-200°C, might be due to loss of absorbed water [24]. The weight loss about 46% occurred in range of 226-328°C due to main decomposition of structure (Figure 5a, b) . This step is an exothermic in nature.
Another degradation with weight loss 25% was observed at 450-570ºC might be due to complete decomposition of husk hydrogels to gaseous products (CO2,CO, and H2O) leaving behind carbon content ash residue. No significant difference among thermal behavior of these fractions was seen. The average Ea values which were found to be 134 kJ mol -1 at multiple heating rates. Using the parameters like IPDT and ITS values (Doyle's method) the thermal stability of all fractions was assessed. The IPDT and ITS values were ranging from 275-305 ºC and 0.43-0.490 respectively. These values indicate that all fractions are fairly stable. FWO method was used to find the Ea values for major stage of decomposition (Table 4) . The FWO and α-T plots for ENa are shown in Figure 6 . The multistep degradation pattern was apparent from variability in Ea with α. 
Isolation of gel fractions
The relative amounts of hydrogels isolated from P. Ovata husk is, AANa (60 percentage) > ENa (44%)> ClfNa (30%)> MNa (50 %)> ANa (20%) ( Figure   1 ).
DR and in vitro buoyancy study
All physical parameters i.e. content uniformity, thickness, weight variation (less than ± 5%), floats size were found in acceptable limits (Table 5 ). Due to best retarding ability of ENa for PRC, it was selected for designing the other formulations. The drug remained within the matrix was relatively greater, therefore new Formulations were designed by changing the amount of variables to increase the availability of drug. The design criteria was as; after 2 h; 25 ± 5%, after 5 h; 45 ± 5% and after 10 h; 65 ± 5%. 1 st batch could not meet the set criteria except S1F9, therefore a 2 nd batch was designed where DR was also less than 25% in 2 h but after 5 h it was very close to stated criteria. After 10 h, release rate was less than 65%. Therefore this batch was also rejected. In 3 rd batch; the DR% in 2 h and 5 h were very close to set target (> 25%, > 45% ) but after 10 h, it was again less than stated criteria. Therefore 4 th batch was designed by replacing TG by LG where DR% was > 25%, > 45% and ≈ 65% for 2 h, 5h and 10h respectively (Table 6 ). So this batch was found to favorable for designing the desired formulations. In 4 th batch, the formulation S4F9 was found to be best fitted due to minimum LT (Table7) and maximum DR % sufficient for achieving the drug plasma level (Figure 7 ).
Kinetic study DR data with all kinetic parameters are given in Table (8-11) . . Time (min) S1F1 S1F2 S1F3 S1F4 S1F5 S1F6 S1F7 S1F8 S1F9 
Similarity and difference factors
The DR profile of all formulations was compared with sustained release marketed tablet and their similarity factors were found to be >50. From these values (Table 12) it was found that their DR mechanism was non-Fickian diffusion. The value of difference factor for no difference lie inbetween 0-15 but most of the formulations deviated from this range showing that their release pattern is anomalous and need to explore further. 
Regression analysis
The regression analysis was conducted to find the effect of variables on drug release rate. The negative sign of factors in equation indicates that its amount should be decreased while positive sign indicates that its amount should be increased to get targeted release rate and mechanism. The effect of all variables in all batches is shown in table 13. The all given plots indicate best correlation between theoretical and experimental drug release profiles. 
Conclusions
All fractions are polysaccharides in nature and due to having swelling, reswelling properties these can be used for designing the sustained release formulations and due to low density they can float over the surface of dissolution medium and hence are suitable for gastro retentive drug release tablets/floats. The Plantago Ovata husk gel has many pharmaceutical properties and is successfully used in diseases like constipation, hyperglycemia and coronary heart diseases. Due to being herbal medicine, they can be successfully applied for designing the controlled release floats. The full factorial design 3 2 reveals that all independent variables shows significant effect on DR rate, lag time and floating time of floats. The SRA (standard regression analysis) shows that the A and B are basic parameters and their alteration can be helpful to achieve the desired DR profile. The positive and negative signs in regression analysis indicates that the value of that variable must be decreased or increased to get required DR profile. Similarity and difference factor is helpful in finding the resemblance or difference with standard DR profile. The thermal study indicates that ENa is thermally stable can withstand environmental changes. The GPC study of these fractions revealed that their PDI values are changing from 2 to 3.74 showing that polymers are poly disperse in nature. All excipients used were herbal in nature and biocompatible to body and are included in GRAS list. Due to these exceptional properties, we can conclude that these fractions are totally safe to use as matrix formation in CDDS, and also have a potential as food preservative films [25].The values of R 2 from kinetic study and RA are helpful in interpreting the nature of matrix. In the last formulation, the value of R 2 for power law 0.965 with n value ≈ 0.482 indicates best fit to required release mechanism. So this formulation was considered to be optimized formulation. 
